OPENING REMARKS

Hamlet BioPharma has conducted three successful Phase II studies, showing efficacy of our drug candidates in three different clinical indications. The second quarter of the fiscal year 2024-2025 has been a period of continued analysis of the three studies, including extensive clinical evaluations and laboratory analyses of effects in treated patients.

Continued progress in our clinical development of our drug candidate Alpha1H for the treatment of bladder cancer

Hamlet BioPharma's drug candidate Alpha1H has shown effective tumor-killing effects in different cancer cells and strong clinical efficacy in controlled clinical trials. The clinical part of the placebo-controlled bladder cancer study has been completed with data lock at the end of 2024. The positive dialogue with the FDA continues, regarding Alpha1H and future studies in bladder cancer patients, with high activity and involvement of clinical collaborators and expert advisors.

Advancing our Immunotherapy - new results show that bacterial infections can be treated by targeting the immune system rather than the bacteria

The company has announced the outcome of a randomized Phase II study, where patients were allocated to antibiotic treatment or anakinra, which modifies the immune response to infection. The results show that bacterial infections can be treated by targeting the immune system rather than the bacteria. This is a conceptual change in this field, where the search for new drugs has focused on finding new antibiotics. Targeting the immune system was as efficient as antibiotics, measured by a significant reduction in symptoms short term and long-term, a lower number of symptomatic recurrences than before the study and an increase in the quality of life. Furthermore, immunotherapy has the potential to reduce the need for antibiotics in large patient groups and potentially the threat of antibiotic resistance.

Financing our portfolio of drug candidates and innovative therapies targeting cancer and infections

Hamlet BioPharma has further completed a directed issue of B-shares, raising approximately SEK 26 million, at low cost. This capital infusion will support the continued development of our innovative therapies targeting cancer and infections. Discussions assisted by our strategic alliances continue, to identify suitable commercial partners for our core assets in cancer and infection. The recent positive Phase II data puts renewed emphasis on the cancer and immunotherapy projects as well as the portfolio of preclinical projects.

We are proud to have taken new discoveries through the drug development process to the clinic and to see positive results in three clinical trials. Hamlet BioPharma continues to drive the clinical programs forward with the goal of bringing these innovative therapies to market. The clinical studies are conducted in collaborations with leaders in the field of cystitis and antibiotic resistance at the University of Giessen, Germany and the field of bladder cancer therapy at the Charles University in Prague, Czechia.

We are grateful to our shareholders for their commitment to the company and trust in our vision. We also thank our competent, multi-national team as well as our external partners and experts for their invaluable contributions.

Catharina Svanborg      Martin Erixon

Chairman of the Board     Chief Executive Officer

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

On October 1, 2024, Hamlet BioPharma invited to a digital event to be held October 9th, where the results from the company's recently completed Phase II clinical study was presented (see video at: https://hamletbiopharma.com/series-of-digital-events).

On October 8, 2024, Hamlet Biopharma published a summary of the company's three Phase II studies showing positive results for patients with recurrent acute cystitis treated with the Interleukin-1 receptor inhibitor anakinra, positive results for patients with severe bladder pain treated with the same substance, and positive results for patients with bladder cancer treated with the investigational new drug Alpha1H.

On October 24, 2024, the company published a notice of the Annual general meeting in Hamlet BioPharma AB, scheduled to take place on November 21st at 15:00 in Malmö.

On October 31, 2024, Hamlet BioPharma published the Annual report for the fiscal year 2023/2024.

On November 4, 2024, Hamlet BioPharma was featured in CEO World Magazine, renowned for its focus on high-level executives and influential business leaders, in their latest Company Spotlight. They highlighted Hamlet BioPharma's recent clinical trials and innovative approach merging groundbreaking research with a strong business vision. 

The featured articles can be read here:

• https://ceoworld.biz/2024/10/29/interview-with-catharina-svanborg-of-hamlet-biopharma/#google_vignette
• https://pulse2.com/hamlet-biopharma-profile-professor-catharina-svanborg-interview/

On November 14, 2024, Hamlet BioPharma invited to a press briefing set to take place on November 18 to present the Q1 report for the 2024/2025 financial year.

On November 15, 2024, Hamlet BioPharma released Q1 Interim Report July 2024 - September 2024 and held a digital investors meeting, where attendees had the opportunity to access important information and ask questions directly to the company's management (see video at: https://hamletbiopharma.com/news/media-archive/).

On November 19, 2024, Hamlet BioPharma announced its participation in the BioStock Life Science Summit 2024 on November 20-21 2024 (see video at: https://hamletbiopharma.com/news/media-archive/).

On November 21, 2024, Hamlet BioPharma published the communiqué from the Annual General Meeting of Hamlet BioPharma AB held on November 21, 2024.

On November 28, 2024, Hamlet BioPharma announced its participation in Økonomisk Ugebrev's Life Science Investor Konference 2024 held on November 27 2024 (see video at: https://hamletbiopharma.com/news/media-archive/).

On December 3, 2024, Hamlet BioPharma announced a directed rights issue of Class B shares. The Directed Issue was carried out based on the authorization granted by the Annual General Meeting on November 21, 2024 at a subscription price of SEK 2.70 per share. The shares were subscribed for by fifteen private investors and family offices. Through the Directed Issue, Hamlet BioPharma raised SEK 26,790,008 before transaction costs.

On December 10, 2024, Hamlet BioPharma announced that the company will present at the Financial Stockholm event, which was held on December 11, 2024 (see video at: https://hamletbiopharma.com/news/media-archive/)

SIGNIFICANT EVENTS AFTER THE FIRST QUARTER

On January 10, 2025, Hamlet BioPharma announced the continuation of the digital event series in the spring of 2025. These events provide participants a valuable opportunity to follow and discuss the drug development process and engage directly with the team during the Q&A sessions that follows each presentation. The event held on January 22nd, included a summary of the rights issue outcome and clinical progress by Catarina Svanborg, as well as an overview of new large-scale technologies, by Assistant Professor Farhan Haq, who works closely with Lund University and performs detailed analyses of clinical samples. (https://hamletbiopharma.com/series-of-digital-events).

On January 29, 2025, the company presented the latest developments at Aktiespararna's digital Life Science-themed evening (https://hamletbiopharma.com/news/media-archive/).

On February 6, 2025, Catharina Svanborg, Lund University and Hamlet BioPharma, was invited to give a talk entitled 'Attacking the Disease Instead of the Bacteria - Immunomodulation as an Alternative to Antibiotics' at the Swedish Research Council's National conference on antibiotic resistance.

COMPANY OVERVIEW

SUCCESSFUL PHASE II STUDIES FOR THREE CLINICAL INDICATIONS

Hamlet BioPharma a pharmaceutical company with a strong portfolio of

project for the treatment of cancer and infections. Hamlet BioPharma has now completed Phase II clinical trials and successfully treated patients with three different diseases.

·    Treating patients with bladder cancer with Alpha1H reduces the number and size of tumors.

·    Treatment of patients with recurrent urinary tract infections with the IL-1 inhibitor anakinra reduces pain and recurrence, with as good effect as antibiotics.

   ·    Treating patients with severe bladder pain with anakinra reduces symptoms, improves quality of life and has positive long-term effects.

Positive Phase II data in three clinical trials

A NEW CLASS OF ANTI-CANCER DRUGS

The HAMLET family of drug candidates effectively kills cancer cells and growing tumor tissue with high precision. In animal models of bladder cancer, colon cancer and brain tumors, HAMLET has shown good treatment effects without damage to healthy tissue. The development also aims to produce drugs for the treatment and prevention of additional cancer indications.

Alpha1H

Our lead compound, Alpha1H represents a new class of cancer drugs with the potential to change cancer treatment. High precision against cancer cells is combined with low toxicity for healthy tissue and broad activity against different cancer cell types. Alpha1H kills cancer cells rapidly, both in the laboratory, in animal models and in treated patients, where the response can be measured within hours.

As the whole HAMLET molecule is difficult to produce, the peptide drug Alpha1H was developed for clinical trials.

Alpha1H contains a synthetic peptide consisting of the N-terminal part of the protein Alpha1, from alpha-lactalbumin.

The Alpha1 peptide binds to oleic acid to form Alpha1H. Alpha1H kills many different cancer cells.

Alpha1H inhibits tumor development in animal models. Alpha1 can be produced synthetically in large quantities.  

Alpha1H treatment is effective against bladder cancer in clinical trials.

BLADDER CANCER

Bladder cancer is a common form of cancer that is difficult to treat, problematic for the patient and costly for society. When treatment is not optimal, the recurrence rate is high, up to 70-80% after the first surgical treatment. Early bladder cancer has the highest recurrence rate and treatment cost per patient among all cancer types (total cost in Europe: >€4.9 billion). Bladder cancer is also one of the most common cancers. According to the latest statistics from the World Cancer Research Fund International, over 614,298 cases of bladder cancer were diagnosed globally in 2022, with a significant proportion being superficial bladder cancer (WCRF International). Bladder cancer is treated with surgery to remove the tumor, followed by chemotherapy or BCG, depending on the severity determined by the tissue pathology. Around 15% of patients with an initial superficial bladder cancer later develop a more severe, muscle-invasive form that can metastasize (Babjuk, Cancer Central).

ALPHA1H TREATMENT OF BLADDER CANCER

Hamlet BioPharma chose early bladder cancer as the first indication based on data from HAMLET-treated patients. There is a great need for new, more effective and safe treatment options for this large and growing patient group. Alpha1H has powerful positive effects in animals with bladder cancer and does not show toxicity. The clinical study program can therefore be designed with great precision.

A randomized, placebo-controlled trial of bladder cancer

A randomized, placebo-controlled study of Alpha1H has been performed at the University Hospital in Prague in collaboration with Hamlet BioPharma and scientists at Lund University. The last part of the study was recently completed. Patients did not experience significant drug related side effects of Alpha1H treatment.

In part I of the study significant treatment effects were detected, compared to placebo. Treatment reduced the tumor size. Cells and tumor fragments detached from the tumor, and analysis of urine samples showed large amounts of drug inside tumor cells The tumor also showed evidence of apoptosis, which is a beneficial form of cell death. Advanced molecular analyses at the RNA and protein levels also showed interesting and specific responses in tumors treated with Alpha1H, switching off the expression of a large number of different cancer genes, which proved to be an important milestone. The successful outcome of the placebo-controlled study was published in Nature Communications (https://doi.org/10.1038/s41467-021-23748-y)

The figure gives an overview of the placebo-controlled study and treatment of bladder cancer with Alpha1H. The images show how Alpha1H is administered and how different effects can be evaluated using clinical techniques and in different patient samples. Patients secrete large amounts of cells, often containing the drug, the tumor shrinks in size and analysis of immune responses provides important information on the effect on tumor tissue.

In Part-2 of the study, increasing doses of Alpha1H were tested to determine the dose that provides optimal patient safety and treatment efficacy. Treatment studies in animal models had shown increasing effects of Alpha1H with increasing doses of Alpha1H, without side effects.

The combined analysis of the two clinical parts has been completed, with extensive analyses of clinical and sample material using different laboratory methods.

1. Reduction in tumor size

• Treatment resulted in a complete or partial response in 88% of tumors treated with 8.l5 mM and in 47% treated with 1.7 mM Alpha1H.

1. Changes in the tumor

• The treatment resulted in the dissolution of the tumor and the release of fragments and cells into the urine. This effect increased significantly with higher doses of Alpha1H.
• The tumor cells died by a mechanism called apoptosis after taking up Alpha1H.
• Pieces of tissue from the tumor that remained in the patient after the treatment had lost some of their tumor characteristics and become more like healthy tissue, as shown by gene expression analysis.

The successful results have been published in Cancer Medicine on 10 September 2024 (https://doi.org/10.1002/cam4.70149) and are summarized below:

Broad immune response with strong anti-tumor potential in bladder cancer patients resembles the response to BCG treatment

The clinical sample analyses have provided important molecular insights into the mechanisms of action of Alpha1H and the tumor response to treatment. The analysis has identified a strong immune response in patients treated with Alpha1H with strong anti-tumor potential. The immune response was rapidly activated by Alpha1H and was shown to increase with the treatment dose.

The activation of the immune system is another important mechanism of action that explains the potential of Alpha1H. Through the immune system, the tumor can be attacked and neutralized, as Alpha1H creates a multifunctional therapeutic environment in the tissue. The manuscript describing this study has been published in Cancer Medicine on 29 March 2024 (https://doi.org/10.1002/cam4.7091).

Dialogue between Hamlet BioPharma and the Food and Drug Administration (FDA)

The company has received Fast Track Designation from the FDA for Alpha1H in the treatment of bladder cancer. The positive dialogue with the FDA is progressing in collaboration with our US affiliate Target Health, Fast Track status provides a number of strategic advantages, including more intensive guidance from the FDA during the clinical development phase of Alpha1H in bladder cancer. This brings Alpha1H closer to the US market and strengthens the company's position for discussions with potential commercial partners.

The next step is for Hamlet BioPharma to obtain FDA approval for the clinical trial program towards Phase III studies.

MARKET OVERVIEW, BLADDER CANCER

The market for superficial bladder cancer was estimated at USD 2.6 billion in 2023, and is expected to grow strongly until 2034, with a then estimated market size of USD 21.1 billion, and a market's compound annual growth rate (CAGR) of around 21.4%. This growth is mainly driven by the cost of new treatments, especially for advanced cancers, and an increased global need for bladder cancer care solutions. The development of immunotherapies and new diagnostic tools is helping to shape an expansive market with increasing costs and a growing focus on improving the quality of life and treatment outcomes for patients suffering from NMIBC (Transparency Market Research).

Source: Transparency Market Research; https://www.transparencymarketresearch.com/non-muscle-invasive-bladder-cancer-market.html

IMMUNOTHERAPY - A NEW WAY TO TREAT BACTERIAL INFECTIONS

Hamlet BioPharma also focuses on developing new drugs for treatment of infections and inflammation. The company is developing immunotherapy for bacterial infections as an alternative to antibiotics. Positive clinical effects have been reported in patients with bladder pain and in patients with recurrent acute cystitis.

Antibiotic resistance is one of the biggest problems of our time and a critical issue for the future. Common bacterial infections, previously treatable, now pose a major threat. Mortality rates increase significantly for severe bacterial infections such as sepsis, pneumonia or kidney infections. As a result, patients with urinary tract infections cannot know whether antibiotics will work or not, and completely different solutions are needed.

Researchers at Lund University, in collaboration with Hamlet BioPharma, have extensive molecular know-how that makes it possible to select compounds suitable for controlling the immune response to infection and reducing disease severity.

One example is Interleukin-1 (IL-1) and its receptor IL-1RA, which is an approved drug, KineretR  (anakinra) inhibits the proinflammatory and potentially destructive effects of IL-1 during acute infection.

RECURRENT ACUTE CYSTITIS

The treatment and management of recurrent UTIs, especially with increasing antibiotic resistance, is a global challenge that also generates high healthcare costs. Recurrent UTIs are usually treated with short courses of antibiotics, and some patients may receive preventive treatment or other non-antibiotic strategies to reduce the risk of future infections.

Hamlet BioPharma has announced positive results from the controlled Phase II clinical trial in patients with recurrent acute cystitis. The study compared antibiotic treatment with immunotherapy (anakinra) in patients with recurrent urinary tract infections, a study conducted in collaboration with specialists in Giessen, Germany. Both treatments showed significant reduction of symptoms and improved quality of life, with no difference in efficacy between the two patient groups.

The clinical results support the use of immunotherapy for recurrent infections, representing a paradigm shift.

Immunotherapy with anakinra can thus reduce the need for antibiotics, which is an important aspect in the fight against resistant bacteria. In addition, the normal bacterial flora can be preserved, which in turn helps to counteract antimicrobial resistance. The next step is a more comprehensive analysis of the study results, which will be submitted for scientific publication.

This approach opens up new possibilities to treat antibiotic-resistant bacteria and shifts the focus from direct elimination of bacteria to strengthening the host's antibacterial defense, offering an alternative solution to the growing global health threat of antibiotic resistance identified by the WHO.

MARKET SIZE- RECURRENT ACUTE CYSTITIS

Source: Data are estimated values to represent market development from reports and research from the American Urological Association (AUA) and International Urogynecology Journal, among others, describing market size and growth trends.

In 2023, the market for the treatment of recurrent UTIs was estimated at around USD 2 billion annually in the US alone, and the global market is expected to grow steadily over the next decade. The market's compound annual growth rate is estimated to be around 6-8% until 2034, driven by increasing prevalence of antibiotic resistance and the need for new treatments, both pharmaceutical and non-antibiotic alternatives. Innovative solutions in antibiotic prophylaxis and preventive treatment with natural products, such as cranberry extract, have also contributed to the expansion of the market (AUA Website) (SpringerLink).

BLADDER PAIN SYNDROME, BPS - A SYNDROME OF SEVERE PAIN IN THE BLADDER

Bladder Pain Syndrome (BPS), also known as interstitial cystitis, is a chronic condition involving bladder pain and severe discomfort, estimated to affect between 4 to 12 million individuals in the United States (approximately 80-90%) (ICHelp)(BladderSmart). (BladderSmart).

Conventional painkillers are not effective, and some patients require morphine treatment or surgery, often without lasting effects. The compound anakinra (IL-1RA), patented by the company for the treatment of bladder pain conditions, has shown promising effects in patients receiving off-label treatment. Pain scores decreased after treatment and quality of life increased in this severely disabled patient group.

In addition, the laboratory tests showed a convincing reduction in pain molecules after treatment, suggesting a direct effect of the treatment at the molecular level. Hamlet BioPharma is therefore continuing the clinical program with a controlled phase II study in this patient group. The study was initiated with a screening phase, to identify patients who responded to treatment. Results of the screening phase were reported in the fourth quarter of 2024. A significant proportion of patients treated with anakinra responded favorably to treatment.

Source: IMARC; https://www.imarcgroup.com/bladder-pain-syndrome-market

Strategic alliances and commercial partnerships

Hamlet BioPharma has engaged in strategic collaborations with leading international advisory firms, to identify partners for the commercialization of company assets.  These partnership strategies have broadened our network within the industry, nationally and internationally. While discussions focus on the lead compound Alpha1H, recent positive Phase II data put renewed emphasis on the immunotherapy projects as well as the portfolio of preclinical projects, to identify new partnerships and strengthen existing networks.

Hamlet BioPharma's pipeline

Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections - has three projects in Phase II clinical trials and additional promising assets with potent effects against infections and cancer in preclinical models, including antibiotic resistant bacteria.

The period in summary

SECOND QUARTER, OCT 1, 2024-DEC 31, 2024 (THE PARENT COMPANY)

- Net sales totaled KSEK 0 (0)

- Other operating income totaled KSEK 0 (30)

- Loss before tax amounted to KSEK -13,888 (-8,655)

- Loss after tax amounted to KSEK -13,888 (-8,655)

- Loss per share* was SEK -0.0782 (-0.0687)

FIRST HALF, JUL 1, 2024-DEC 31, 2024 (THE PARENT COMPANY)

- Net sales totaled KSEK 0 (0)

- Other operating income totaled KSEK 0 (38)

- Loss before tax amounted to KSEK -23,654 (-16,984)

- Loss after tax amounted to KSEK -23,654 (-16,984)

- Loss per share* was SEK -0.1331 (-0.1348)

- On December 31, 2024, the equity/assets ratio** was 93.1 (84.9) %

SECOND QUARTER, OCT 1, 2024-DEC 31, 2024 (THE GROUP)

- Net sales totaled KSEK 0 (0)

- Other operating income totaled KSEK 0 (38)

- Loss before tax amounted to KSEK -14,387 (-9,154)

- Loss after tax amounted to KSEK -14,387 (-9,154)

- Loss per share* was SEK -0.0810 (-0.0726)

FIRST HALF, JUL 1, 2024-DEC 31, 2024 (THE GROUP)

- Net sales totaled KSEK 0 (0)

- Other operating income totaled KSEK  (38)

- Loss before tax amounted to KSEK -24,651 (-17,982)

- Loss after tax amounted to KSEK -24,651 (-17,982)

- Loss per share* was SEK -0.1387 (-0.1427)

- On December 31, 2024, the equity/assets ratio** was 92.8 (84.5) %

Amounts in parentheses above and below indicate the corresponding value in the preceding year.

* Profit/loss after tax for the period divided by 177,685,127 (126,006,368), respectively, where 177,385,127 is the number of shares outstanding on December 31, 2024, the comparative figure in parentheses was the number of shares on December 31, 2023.

** Equity divided by total capital.

Revenue and earnings

The costs for the merged companies Hamlet BioPharma and SelectImmune Pharma reflect the larger project portfolio and the costs of the three clinical trials in Phase II. Hamlet BioPharma's net sales amounted to KSEK 0 (0) during the second quarter. Other operating income amounted to KSEK 0 (30) during the quarter. Costs were related to the continued drug development activities of the research team at Lund University. The team at Lund University is also responsible for the development of manufacturing methods, stability testing, and chemical and functional characterization of existing and new drug substances and plays a key role in the coordination of laboratory testing in the clinical trial. Costs in the group accounting consists of depreciation of patent from the acquirement of Linnane Projects AB.

Loss before tax for the parent company for the second quarter was KSEK -13,888

(-8,655), and for the first half KSEK -23,654 (-16,984). Loss before tax for the group for the second quarter was KSEK -14,387 (-9,154), and for the first half KSEK -24,651 (-17,982).

Financial position

The Company successfully completed a directed rights issue during December 2024, which raised MSEK 26.5 for the Company after issue costs of only KSEK 277.

At the end of the second quarter, the equity/assets ratio was 93.1 (84.9) %, and the Company's cash and cash equivalents were KSEK 30,391 (6,205).

Investments

The Company does not capitalize expenses for research and development as assets, since the Company is in an R&D stage. R&D costs are therefore recognized as operating expenses in the income statement.

During the quarter computer equipment of 25 KSEK was purchased.

Depreciation

During the quarter, depreciation of equipment amounted to KSEK 114 (101), and the depreciation of patents from the merger with SelectImmune Pharma AB amounted to KSEK 2,021 (2,021).

In the group, depreciation of patents, including the acquisition of Linnane Projects AB, amounted to KSEK 2,520 (2,520) during the quarter.

Employees

The company had the equivalent of 7 (7) full-time employees during the quarter

The share

The Company's shares have been traded on Spotlight Stock Market since October 23, 2015. The share is traded under the short name "HAMLET B" with ISIN code SE0015661152.

At the extraordinary general meeting in Hamlet Pharma AB on March 2, 2021, it was decided that the company's common shares would undergo a split with relation 3:1 and would be reclassified as A- and B-shares. The B-shares will be traded on Spotlight Stock Market. The A-shares will not be listed. Each A-share entitles to ten votes and B-shares entitles to one vote. Furthermore, it is possible for shareholders to convert A-shares to B-shares, which can be traded on Spotlight Stock Market. This conversion program is ongoing with no current deadline. This means that the ratio between A- and B-shares will change over time.

As of December 31, 2024, the number of shares registered at the Swedish Companies Registration Office (Bolagsverket) totaled 177,685,127. As of January 27, 2025, the registered current ratio of shares was 39,949,156 A-shares and 137,735,971 B-shares.

Subscription warrants

The company had no outstanding warrants as of December 31, 2024.

Transactions with related parties

During the quarter, KSEK 1,370 (1,370) was paid to Linnane Pharma AB, of which KSEK 1,250 (1,250) refers to the co-operation agreement, and KSEK 120 (120) refers to patent license.

The collaboration agreement grants access to advanced science and cutting-edge technology for drug development. The collaboration means that Linnane Pharma's technology platform and other resources are available to Hamlet BioPharma. Hamlet BioPharma is a subsidiary company of Linnane Pharma AB, which owns 34.28% of the capital and 74.84% of the votes of Hamlet BioPharma. Catharina Svanborg, Chairman of Hamlet BioPharma, is the main owner of Linnane Pharma AB.

Furthermore, salaries and allowances to board and management were paid during the period. Transactions with related parties are on market terms.

Significant risks and uncertainties

The Board's assessment of significant risks and uncertainties is unchanged compared with the most recent financial year and is described in the most recently published annual report (2024-06-30).

Basis of preparation for the interim report

The Company prepares its accounts in accordance with the Swedish Annual Accounts Act (Årsredovisningslagen) and the K3 framework (BFNAR 2012:1) of the Swedish Accounting Standards Board (Bokföringsnämnden).

The company's accounting principles are unchanged compared with most recent financial year and are described in the most recently published annual report (2024-06-30).

On March 31st, 2023, Hamlet BioPharma acquired Linnane Projects AB from Linnane Pharma AB and the patents and know-how regarding a new peptide-based drug against tuberculosis as well as the know-how required to develop the project. In accordance with regulations at Spotlight and the Swedish Accounting Standards Board (Bokföringsnämnden), consolidated accounts of Linnane Projects and Hamlet BioPharma are drawn up.  The quarterly report is prepared with the parent company's accounting in focus. In texts, the group is only commented on if something differs significantly from the parent company.

Review

This interim report has not been audited.

Financial calendar

Interim report for Q3, 2024/2025 May 22, 2025

Year-end report (Q4), 2024/2025 August 28, 2025

Annual report for 2024/2025 October 31, 2025

Interim report for Q1, 2025/2026 November 14, 2025

Annual General Meeting for 2024/2025 November 20, 2025

Income Statement : The Parent Company

Balance Sheet : The Parent Company

Cash Flow Statement : The Parent Company

Equity : The Parent Company

Income Statement : The Group

Balance Sheet : The Group

Cash Flow Statement : The Group

Equity : The Group

The Board of Directors and the Chief Executive Officer assure that the interim report provides a true and fair view of the Company's operations, position, and results.

Malmö, February 13 , 2025

 Catharina Svanborg Martin Erixon

 Chairman of the Board CEO

 Bill Hansson Helena Lomberg

 Board member Board member

 Magnus Nylén Elisabeth Parker

 Board member Board member

 Ulla Trägårdh 

 Board member